13F Holdings
中文EN

VNRX VOLITIONRX LTD

In Vitro & In Vivo Diagnostic Substances · NYSE · SEC CIK 93314 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY134.0%
TTM net income YoY-3.8%
TTM EPS YoY62.7%
Revenue 3-yr CAGR74.3%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-512.6%
Net margin-698.5%
FCF margin-597.6%
EBITDA margin-489.2%

Returns

ROE—
ROA-352.5%
ROIC (approx.)—
Asset turnover0.50x

Leverage & solvency

Liabilities / assets481.7%
Debt / equity—
Current ratio0.33x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.85x
Accruals ratio-51.9%
Payout ratio—
Capex / revenue2.0%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$1.73M$1.23M$775,302$306,392$90,035
R&D expense$10.08M$14.41M$19.55M$15.33M$13.02M
SG&A expense$9.46M$8.49M$10.37M$10.18M$11.68M
Operating income-$21.74M-$27.02M-$35.99M-$31.78M-$28.33M
Interest expense————$155,803
Net income-$23.36M-$26.97M-$35.68M-$30.60M-$26.99M
EBITDA-$20.75M-$25.91M-$34.84M-$30.84M-$27.39M
EPS (basic)————-0.51
EPS (diluted)—-0.31-0.50—-0.51
Weighted avg. shares (diluted)106.83M86.53M71.23M—52.66M
Balance sheet
Cash & equivalents$1.12M$3.26M$20.73M$10.87M$20.58M
Receivables$317,808$110,574$242,617$72,609$12,510
Current assets$2.06M$4.06M$21.85M$12.17M$21.98M
PP&E, net$4.03M$4.43M$5.52M$5.39M$4.91M
Intangibles$316,704$313,747$23,886$110,505$216,876
Total assets$6.90M$9.40M$27.95M$18.30M$27.49M
Current liabilities$12.23M$7.79M$8.94M$17.39M$6.52M
Short-term debt$890,571$860,223$1.21M$1.07M$797,855
Long-term debt$5.82M$3.95M$3.62M$2.78M$2.27M
Total debt$6.71M$4.81M$4.83M$3.85M$3.07M
Total liabilities$42.49M$35.51M$36.66M$21.42M$9.77M
Shareholders' equity-$34.25M-$24.91M-$7.80M-$2.57M$17.72M
Net debt$5.59M$1.55M-$15.90M-$7.02M-$17.51M
Shares outstanding6.29M96.10M81.90M57.87M53.77M
Cash flow statement
Operating cash flow-$19.68M-$25.89M-$18.06M-$15.28M-$20.85M
Capital expenditure$89,558$277,499$1.08M$1.57M$973,559
Free cash flow-$19.77M-$26.17M-$19.15M-$16.85M-$21.83M
Investing cash flow-$89,558-$573,852-$1.08M-$1.57M-$973,559
Financing cash flow$17.09M$8.66M$28.98M$6.94M$22.86M
Depreciation & amortization$983,706$1.11M$1.15M$936,084$945,367
Stock-based compensation$1.74M$1.27M$2.29M$3.11M$2.45M
Share buybacks—$0$31,772$0—

Free plan shows the latest 5 periods; Pro shows all 15 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.